Is deacetylase inhibitor Dinaciclib Worth The Money?

omboembolic complicationsin patients undergoing orthopedic surgery. Willthese new anticoagulants have a deacetylase inhibitor real impact on thromboembolicprevention, especially stroke, in patients withAF? After presenting comparative studies in deacetylase inhibitor the followingparagraphs, the advantages and disadvantages inrelation to warfarin are discussed.Dabigatran etexilate is a prodrug that becomes theactive principle dabigatran with specific inhibiting effectsof thrombin both free and bound to fibrin. In the RE-LYstudydabigatran was administered intwo dosages: 150 mg or 110 mg twice daily. The resultsbased on the criterion of noninferiority indicate that thedosage of 150 mg twice a day was significantly moreeffective than warfarin in the prevention of ischemicstroke with similar frequency of hemorrhagic stroke.
The dosage of 110 mg twice a day was similar to warfarinin the prevention of thromboembolism and presentedwith lower hemorrhagic events. Patients treatedwith a dosage of 150 mg twice daily had a 35% reductionin systemic embolism and 74% of the risk ofhemorrhagic stroke. These numbers are impressive.The NNT can describe results from the perspective Dinaciclib ofdaily medical practice. Although the differencesbetween dabigatran and warfarin in some of theoutcomes are significant and related to the number ofpatients included, the NNT of the endpoints are unconvincing and the 35% reduction instroke does not seem as impressive. Results from phaseIV studies would provide more data on efficacy andsafety ratios.When the side effects are considered, it isperhaps still premature to advocate this medication.
Forexample, the end points do not take into account minorbleeding, which, although it does not complicate theclinical evolution of patients, can result in the suspensionof medication and a transient prothrombotic state.Moreover, patients in the dabigatran group discontinuedthe medication in larger numbers than those with warfarin,because of gastrointestinal symptoms. Myocardialinfarction was PARP also was more common in patients treatedwith dabigatran.In certain circumstances, the triple combination of aspirin,clopidogrel and oral anticoagulants is required. Oldgrenet al.compared triple therapy with dabigatran inpatients with recent myocardial infarction. Their studyshowed that 3.8% of patients taking placebo died or hada heart attack or stroke compared with dabigatran atdifferent doses, twice daily; 4.
6% in those treated with50 mg, 4.9% for 75 mg; 3.0% for 110 mg and 3.5% for150 mg. Hemorrhagesduring the 6-month treatment periodincreased dose-dependently with dabigatran: the hazardratio was 1.77 for 50 mg, 2.17 for 75 mg, 3.92 for 110mg, and 4.27 for 150 mg compared with placebo.It is interesting that the US Food and Drug Administrationapproved the 150 mg twice Dinaciclib daily dosagebut not the lower dose and instead approved a 75 mgtwice daily dosage for patients with renal insufficiencywith creatinine clearance less than 30 mL/min. This issupported by the Oasis 6 study, in which a statisticallysignificant increase in bleeding was observed inpatients with creatinine clearance ≤30 mL/min whenusing enoxaparin.To investigate 110 mg dose, Eikelboom et al.
compared hemorrhagic stroke in patients from deacetylase inhibitor the RELYstudy who were older and younger than 75 yearsand found that both doses of dabigatran have lowerrisks of both intracranial and extracranial bleeding inpatients aged Rivaroxaban dosage was 15-20 mg/day and warfarin planned to maintain an INR of 2.0-3.0.The primary end point was a reduction in embolic eventsand evaluation of bleeding Dinaciclib complications.The same criteria as for dabigatran can be appliedwith regard to the NNT. For someprimary outcomes where the difference with warfarin issignificant P < 0.001), at least 192 patients must be treatedin daily practice to prevent 1 case of vascular death,stroke, or embolism.The study results showed that rivaroxaban significantlyreduced intracranial bleeding compared with warfarin.With regard this safety point, between 278 and417 patients must be treated to obtain 1 case of reductionin critical organ bleeding or bleeding causing deathor intracranial hemorrhage in favor of rivaroxaban.The MAGELLAN studyis an approach on security in nonsurgicalpatients and serves to maintain alert about the hemorrhagicpossibilities. Eight thousand one hundred andone patients were randomized to 10 mg rivaroxabanonce daily for 35 days or standard trea